Fierce Pharma
NOVEMBER 17, 2023
After the landmark success of Enhertu in HER2-low breast cancer, AstraZeneca has blazed another trail in the world’s most common cancer type. | After the landmark success of Enhertu in HER2-low breast cancer, AstraZeneca has blazed another trail in the world’s most common cancer type. But an unexpected restriction has cast a dark cloud over the first-in-class approval.
MedCity News
NOVEMBER 17, 2023
Automation can be a powerful tool to bring together all the pieces needed to provide optimal care that can be scattered across various systems and apps. Whether it’s to exchange patient data quickly and easily, identify communities in need of programs to address food inequity, or reduce no-shows by sending automatic reminders, using the right technology is an essential tool for achieving better patient care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 17, 2023
Amid a corporate review of AstraZeneca’s global manufacturing and supply network, the company’s Indian subsidiary is planning to close up shop at the “beating heart” of its India operations in Bang | AstraZeneca Pharma India will exit its production plant in Bangalore, India, “in due course,” the company said in a filing. AZ plans to find a buyer who can also serve as a contract manufacturer for the drugs produced there.
MedCity News
NOVEMBER 17, 2023
A recent report from Papa, a companion care company, found that 22% of Medicare Advantage members are severely lonely. The findings give some insights into why employers and payers should offer companion support, according to Andrew Parker, founder and CEO of Papa.
Fierce Pharma
NOVEMBER 17, 2023
The FDA has signed off on label expansions for two of the world’s most important cancer medicines—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. | The FDA has signed off on label expansions for two of the world’s most important cancer medicines—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expansion is in stomach cancer. Xtandi’s new indication expands its already deep portfolio in the treatment of prostate cancer.
MedCity News
NOVEMBER 17, 2023
Abbott’s new leadless pacemaker system has become commercially available and has begun being implanted in people at hospitals across the nation. Most people who need a pacemaker require pacing in two chambers of the heart, and the dual-chamber technology in Abbott’s new system allows these patients to have a leadless pacemaker.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 17, 2023
The healthcare IT industry is in a state of constant evolution, with regulatory trends shaping the path forward. Continuous updates in certification regulations, the integration of emerging technologies, and data privacy concerns are just some of the challenges facing healthcare IT stakeholders.
Fierce Pharma
NOVEMBER 17, 2023
In response to a supply squeeze for Sanofi and AstraZeneca’s respiratory syncytial virus (RSV) antibody Beyfortus, the U.S. | Sanofi and AstraZeneca's highly anticipated infant RSV immunization ran into supply issues just a few months into its launch. In response, government officials are speeding more doses into distribution.
MedCity News
NOVEMBER 17, 2023
The FDA approved AstraZeneca’s Truqap as a new treatment for advanced cases of breast cancer. The drug is the first in a new class of therapies addressing AKT genetic alterations.
Pharmaceutical Technology
NOVEMBER 17, 2023
Micron Biomedical has received $23.6m in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
NOVEMBER 17, 2023
The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.
MedCity News
NOVEMBER 17, 2023
It’s not just our lowest-paid healthcare professionals who suffer from financial insecurity. From the hardworking custodian to the extremely specialized surgeon, all healthcare professionals should be offered the resources and means to keep up with inflation and financial concerns.
PharmaTimes
NOVEMBER 17, 2023
The AI system will identify those most at risk and reduce pressure on the NHS - News - PharmaTimes
Pharmaceutical Commerce
NOVEMBER 17, 2023
With new mandates right around the corner, there is an unwavering demand for pharma operations to perform at peak efficieny.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
NOVEMBER 17, 2023
The European Commission has approved Ebglyss (lebrikizumab) for atopic dermatitis patients 12 years and older with a body weight of at least 40kg, who are candidates for systemic therapy. Almirall has licensed the rights to develop and commercialise lebrikizumab for the treatment of dermatology indications in Europe. The company said it will launch lebrikizumab in Germany, with further European rollout planned throughout 2024.
Pharmaceutical Technology
NOVEMBER 17, 2023
Daiichi Sankyo has signed an agreement with Japan's MHLW to deliver 1.4 million doses of its omicron-adapted mRNA vaccine for Covid-19.
PharmExec
NOVEMBER 17, 2023
Shields discusses Ferring’s recent $5 million endowment to the American Society of Reproductive Medicine.
European Pharmaceutical Review
NOVEMBER 17, 2023
Results from AbbVie’s Phase III study, PRODROME , published in The Lancet showed that UBRELVY ® (ubrogepant) 100mg for acute treatment of migraine significantly reduced the likelihood of development of moderate or severe headache compared to placebo within 24 hours post-dose. This was demonstrated when the calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) was administered during the prodrome phase (ie, one to sixurs before the predicted onset of headache pain) of a migraine a
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmExec
NOVEMBER 17, 2023
Heliyon study evaluates online information, labeling accuracy, and quantitative analysis of high peroxide content gels.
Healthcare Success
NOVEMBER 17, 2023
Have your products, services, or target audience evolved to the point where they no longer align with your brand? Has your health brand become lost in a sea of sameness? Do your marketing assets feel stale and out of touch with your audience? Did your business neglect to establish proper healthcare branding from the beginning? Whether your current branding isn’t servicing your business anymore or your brand has evolved beyond your existing branding—it’s time for a rebrand.
MedCity News
NOVEMBER 17, 2023
Check out news from Harmony Health Foundation, Gratia Health, Pathway, Fortuna Health, and more.
PharmaTimes
NOVEMBER 17, 2023
The University of Leeds and NHS organisations will host the network in 2024 - News - PharmaTimes
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Copyright Clearance Center
NOVEMBER 17, 2023
The post Hachette Restructures appeared first on Copyright Clearance Center.
pharmaphorum
NOVEMBER 17, 2023
Digital health company BehaVR hits the merger trail again Phil.
Spotio
NOVEMBER 17, 2023
Looking to sell more roofs for your roofing business? Proven roofing sales training will help you (or your reps) connect with more customers and close more deals. The question is, which sales training for roofing companies is best? We aim to answer that for you in this article. Keep reading to learn about six specific programs you can use to take your roofing venture to the next level.
pharmaphorum
NOVEMBER 17, 2023
FDA’s Janet Woodcock will step down early next year Phil.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Clarify Health
NOVEMBER 17, 2023
In this video, Emily Roesing , Senior Director of Product at Clarify Health, discusses how to influence specialist referral and facility selection at the point of care. Transcript I have spent many years focused on finding solutions that will help both payers and providers tackle this question: How can we get patients to visit the best possible specialists and receive care at the right facilities?
Cesare Ferrari
NOVEMBER 17, 2023
Consider this: You worked hard to find and select a new commercial partner in an uncovered market. You and your new distributor invested time and resources to establish what both expect to be a long-term, profitable and fruitful commercial relationship. All the prerequisites are fulfilled, the distribution agreement is signed, and the regulatory departments are working together in harmony to register the products.
Pharmaceutical Commerce
NOVEMBER 17, 2023
Pembrolizumab (Keytruda) plus fluoropyrimidine- and platinum-containing chemotherapy for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction cancer approved by FDA after being found to lower the risk of metastasis or death.
PharmExec
NOVEMBER 17, 2023
Enzalutamide (Xtandi) from Astellas Pharma Inc. and Pfizer Inc. gets FDA approval to treat nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
277 
Let's personalize your content